Kraj: Unia Europejska
Język: angielski
Źródło: EMA (European Medicines Agency)
doripenem
Janssen-Cilag International NV
J01DH04
doripenem
Antibacterials for systemic use,
Pneumonia, Ventilator-Associated; Pneumonia, Bacterial; Urinary Tract Infections; Bacterial Infections; Cross Infection
Doribax is indicated for the treatment of the following infections in adults:nosocomial pneumonia (including ventilator-associated pneumonia);complicated intra-abdominal infections;complicated urinary tract infections.Consideration should be given to official guidance on the appropriate use of antibacterial agents.
Revision: 10
Withdrawn
2008-07-25
38 B. PACKAGE LEAFLET Medicinal product no longer authorised 39 PACKAGE LEAFLET: INFORMATION FOR THE USER DORIBAX 250 MG POWDER FOR SOLUTION FOR INFUSION doripenem READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor, pharmacist or nurse. - If you get any side effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet. WHAT IS IN THIS LEAFLET 1. What Doribax is and what it is used for 2. What you need to know before you use Doribax 3. How to use Doribax 4. Possible side effects 5. How to store Doribax 6. Contents of the pack and other information 1. WHAT DORIBAX IS AND WHAT IT IS USED FOR Doribax contains the active substance doripenem. This medicine is an antibiotic which works by killing different types of bacteria (germs) that cause infections in various parts of the body. Doribax is used to treat adults for the following infections: - Pneumonia (a serious type of chest or lung infection) that you catch in a hospital or similar setting. This includes pneumonia that you catch when on a machine that helps you breathe. - Complicated infections of the area around your stomach (abdominal infections). - Complicated urinary tract infections, including kidney infections and cases that have spread to the bloodstream. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE DORIBAX DO NOT USE DORIBAX: - If you are allergic to doripenem. - If you are allergic to other antibiotics such as penicillins, cephalosporins or carbapenems (which are used to treat various infections) as you may also be allergic to Doribax. Do not use this medicine if any of the above applies to you. If you are not sure, talk to your doctor, pharmacist or nurse before being given Doribax. WARNINGS AND PRECAUTIONS Talk to your doctor, pharmacist or nurse before being given Doribax, and if you have: - Kidney problems. Your doctor may nee Przeczytaj cały dokument
1 ANNEX I SUMMARY OF PRODUCT CHARACTERISTICS Medicinal product no longer authorised 2 1. NAME OF THE MEDICINAL PRODUCT Doribax 250 mg powder for solution for infusion 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each vial contains doripenem monohydrate equivalent to 250 mg doripenem. 3. PHARMACEUTICAL FORM Powder for solution for infusion (powder for infusion) White to slightly yellowish off-white crystalline powder 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Doribax is indicated for the treatment of the following infections in adults (see sections 4.4 and 5.1): ● Nosocomial pneumonia (including ventilator–associated pneumonia) ● Complicated intra-abdominal infections ● Complicated urinary tract infections Consideration should be given to official guidance on the appropriate use of antibacterial agents. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose and administration by infection is shown in the following table: Infection Dose Frequency Infusion time Nosocomial pneumonia including ventilator–associated pneumonia 500 mg or 1 g* every 8 hours 1 or 4 hours** Complicated intra-abdominal infection 500 mg every 8 hours 1 hour Complicated UTI, including pyelonephritis 500 mg every 8 hours 1 hour * 1 g every 8 hours as a 4-hour infusion may be considered in patients with augmented renal clearance (particularly those with creatinine clearance (CrCl) ≥ 150 ml/min) and/or in infections due to non-fermenting gram-negative pathogens (such as _Pseudomonas_ spp. and _Acinetobacter_ spp.). This dose regimen is based on PK/PD data (see sections 4.4, 4.8 and 5.1). ** Based mainly on PK/PD considerations, a 4-hour infusion time may be more suitable for infection with less susceptible pathogens (see section 5.1). This dosing regimen should also be considered in particularly severe infections. _Duration of treatment_ The usual treatment duration of doripenem therapy ranges from 5-14 days and should be guided by the severity, site of the infection, infecting pathogen and the patient’s cli Przeczytaj cały dokument